These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30803726)

  • 41.
    Pragsam AK; Kumar DT; Doss CGP; Iyadurai R; Satyendra S; Rodrigues C; Joshi S; Roy I; Chaudhuri BN; Chitnis DS; Tapan D; Veeraraghavan B
    Indian J Med Microbiol; 2018; 36(1):127-130. PubMed ID: 29735843
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa.
    Teo JQ; Lim JC; Tang CY; Lee SJ; Tan SH; Sim JH; Ong RT; Kwa AL
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33504661
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states.
    Velez Perez AL; Schmidt-Malan SM; Kohner PC; Karau MJ; Greenwood-Quaintance KE; Patel R
    Diagn Microbiol Infect Dis; 2016 Jul; 85(3):356-359. PubMed ID: 27130477
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program.
    Sader HS; Flamm RK; Carvalhaes CG; Castanheira M
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224535
    [No Abstract]   [Full Text] [Related]  

  • 45. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Seifert H; Körber-Irrgang B; Kresken M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain.
    Maruri-Aransolo A; López-Causapé C; Hernández-García M; García-Castillo M; Caballero-Pérez JD; Oliver A; Cantón R
    J Antimicrob Chemother; 2024 Jun; 79(6):1432-1440. PubMed ID: 38708553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece.
    Galani I; Papoutsaki V; Karantani I; Karaiskos I; Galani L; Adamou P; Deliolanis I; Kodonaki A; Papadogeorgaki E; Markopoulou M; Maraki S; Damala M; Prifti E; Vagiakou E; Petinaki E; Fountoulis K; Tsiplakou S; Kirikou H; Souli M; Antoniadou A; Giamarellou H
    J Antimicrob Chemother; 2020 Aug; 75(8):2164-2172. PubMed ID: 32449909
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis.
    Lee AC; Jones AL
    Paediatr Respir Rev; 2018 Jun; 27():18-20. PubMed ID: 29914746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.
    Del Barrio-Tofiño E; López-Causapé C; Cabot G; Rivera A; Benito N; Segura C; Montero MM; Sorlí L; Tubau F; Gómez-Zorrilla S; Tormo N; Durá-Navarro R; Viedma E; Resino-Foz E; Fernández-Martínez M; González-Rico C; Alejo-Cancho I; Martínez JA; Labayru-Echverria C; Dueñas C; Ayestarán I; Zamorano L; Martinez-Martinez L; Horcajada JP; Oliver A
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874376
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18.
    Sader HS; Carvalhaes CG; Duncan LR; Flamm RK; Shortridge D
    J Antimicrob Chemother; 2020 Oct; 75(10):2907-2913. PubMed ID: 32653914
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
    Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa.
    Sader HS; Flamm RK; Dale GE; Rhomberg PR; Castanheira M
    J Antimicrob Chemother; 2018 Sep; 73(9):2400-2404. PubMed ID: 29901750
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ; Sader HS; Flamm RK; Jones RN
    Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    Grohs P; Taieb G; Morand P; Kaibi I; Podglajen I; Lavollay M; Mainardi JL; Compain F
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096165
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mechanisms of high-level ceftolozane/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin.
    So W; Shurko J; Galega R; Quilitz R; Greene JN; Lee GC
    J Antimicrob Chemother; 2019 Jan; 74(1):269-271. PubMed ID: 30295837
    [No Abstract]   [Full Text] [Related]  

  • 57. Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients.
    Finklea JD; Hollaway R; Lowe K; Lee F; Le J; Jain R
    Diagn Microbiol Infect Dis; 2018 Sep; 92(1):75-77. PubMed ID: 29884565
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trends of Antimicrobial Resistance and Combination Susceptibility Testing of Multidrug-Resistant Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients: a 10-Year Update.
    Okoliegbe IN; Hijazi K; Cooper K; Ironside C; Gould IM
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33820772
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa.
    Xipell M; Paredes S; Fresco L; Bodro M; Marco F; Martínez JA; Soriano A
    J Glob Antimicrob Resist; 2018 Jun; 13():165-170. PubMed ID: 29366723
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates.
    Skoglund E; Ledesma KR; Lasco TM; Tam VH
    J Glob Antimicrob Resist; 2017 Dec; 11():154-155. PubMed ID: 29101084
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.